FXR1 was another important RBP for non‐small cell lung cancer (NSCLC) development, and research has found that its expression was a candidate biomarker for poor survival in a variety of solid tumors, including NSCLC. The gene discussed is FXR1; the disease is non-small cell lung carcinoma.